The Significance of Defensin Alpha 4 in the Pathophysiology of the Adrenal Insufficiency in Inflammatory Lung Diseases
1 other identifier
observational
75
0 countries
N/A
Brief Summary
The pathophysiology of the adrenal insufficiency of patients with critical diseases remains unclear. In a prior exploratory study investigating patients with exacerbation of chronic obstructive pulmonary disease (COPD), the investigators demonstrated a highly significant correlation between the expression level of Defensin-alpha 4 (DEFA4) mRNA in blood and the adrenal function assessed via low-dose ACTH tests. The aim of this prospective study is to demonstrate that DEFA4 measured both at the mRNA level (RT-PCR) and at the protein level (Western blot/Elisa) is a reliable biomarker for the prediction of adrenal insufficiency in inflammatory lung diseases (patients with COPD and pneumonia).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 5, 2012
CompletedFirst Posted
Study publicly available on registry
October 10, 2012
CompletedStudy Start
First participant enrolled
January 1, 2013
CompletedOctober 10, 2012
October 1, 2012
October 5, 2012
October 9, 2012
Conditions
Keywords
Eligibility Criteria
Pneumonia patients (n=30) COPD patients (n=30) Healthy controls (n=15)
You may qualify if:
- Patients 18-80 yo
- Patients diagnosed with pneumonia or exacerbated COPD
- Healthy controls 18-80yo
- Signed informed consent
You may not qualify if:
- Pregnant or lactating females
- Life threatening severe disease
- Known primary or secondary adrenal insufficiency
- Systemic steroid therapy in the last 8 weeks
- Systemic therapy with opioid
- Systemic therapy with Ketoconazol, Mitotane, Metopyron, Etomidat, Rifampicin
- In healthy controls: relevant respiratory disease or known adrenal insufficiency or indication of infection
- Allergic reaction to ACTH
- Missing informed consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Biospecimen
Blood leukocytes, serum
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Prof.
Study Record Dates
First Submitted
October 5, 2012
First Posted
October 10, 2012
Study Start
January 1, 2013
Last Updated
October 10, 2012
Record last verified: 2012-10